198 related articles for article (PubMed ID: 34592434)
21. The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation.
Nalbandian G; Paharkova-Vatchkova V; Mao A; Nale S; Kovats S
J Immunol; 2005 Aug; 175(4):2666-75. PubMed ID: 16081843
[TBL] [Abstract][Full Text] [Related]
22. Selective estrogen receptor modulators: tissue selectivity and differential uterine effects.
Silfen SL; Ciaccia AV; Bryant HU
Climacteric; 1999 Dec; 2(4):268-83. PubMed ID: 11910661
[TBL] [Abstract][Full Text] [Related]
23. Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance.
Sengupta S; Jordan VC
Adv Exp Med Biol; 2008; 630():206-19. PubMed ID: 18637493
[TBL] [Abstract][Full Text] [Related]
24. Antiestrogens: structure-activity relationships and use in breast cancer treatment.
Traboulsi T; El Ezzy M; Gleason JL; Mader S
J Mol Endocrinol; 2017 Jan; 58(1):R15-R31. PubMed ID: 27729460
[TBL] [Abstract][Full Text] [Related]
25. Tamoxifen prevention of breast cancer: an instance of the fingerpost.
Lippman SM; Brown PH
J Natl Cancer Inst; 1999 Nov; 91(21):1809-19. PubMed ID: 10547388
[No Abstract] [Full Text] [Related]
26. Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs).
Musa MA; Khan MO; Cooperwood JS
Curr Med Chem; 2007; 14(11):1249-61. PubMed ID: 17504144
[TBL] [Abstract][Full Text] [Related]
27. Chemoprevention of breast cancer.
O'Regan RM; Jordan VC
Cancer Treat Res; 2001; 106():137-54. PubMed ID: 11225001
[No Abstract] [Full Text] [Related]
28. Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells.
Dardes RC; Schafer JM; Pearce ST; Osipo C; Chen B; Jordan VC
Gynecol Oncol; 2002 Jun; 85(3):498-506. PubMed ID: 12051881
[TBL] [Abstract][Full Text] [Related]
29. Prevention of breast cancer: current state of the science and future opportunities.
Uray IP; Brown PH
Expert Opin Investig Drugs; 2006 Dec; 15(12):1583-600. PubMed ID: 17107283
[TBL] [Abstract][Full Text] [Related]
30. Differential SERM effects on corepressor binding dictate ERalpha activity in vivo.
Webb P; Nguyen P; Kushner PJ
J Biol Chem; 2003 Feb; 278(9):6912-20. PubMed ID: 12482846
[TBL] [Abstract][Full Text] [Related]
31. The endometrial effects of SERMs.
Cano A; Hermenegildo C
Hum Reprod Update; 2000; 6(3):244-54. PubMed ID: 10874569
[TBL] [Abstract][Full Text] [Related]
32. Differential SERM activation of the estrogen receptors (ERalpha and ERbeta) at AP-1 sites.
Weatherman RV; Clegg NJ; Scanlan TS
Chem Biol; 2001 May; 8(5):427-36. PubMed ID: 11358690
[TBL] [Abstract][Full Text] [Related]
33. A precisely substituted benzopyran targets androgen refractory prostate cancer cells through selective modulation of estrogen receptors.
Kumar R; Verma V; Sharma V; Jain A; Singh V; Sarswat A; Maikhuri JP; Sharma VL; Gupta G
Toxicol Appl Pharmacol; 2015 Mar; 283(3):187-97. PubMed ID: 25655200
[TBL] [Abstract][Full Text] [Related]
34. Development of cross-resistance to tamoxifen in raloxifene-treated breast carcinoma cells.
Gao ZO; Gao ZP; Fields JZ; Boman BM
Anticancer Res; 2002; 22(3):1379-83. PubMed ID: 12168814
[TBL] [Abstract][Full Text] [Related]
35. Playing the old piano: another tune for endocrine therapy?
Hayes DF
J Natl Cancer Inst; 2003 Nov; 95(21):1565-7. PubMed ID: 14600082
[No Abstract] [Full Text] [Related]
36. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
Pickar JH; Komm BS
Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836
[TBL] [Abstract][Full Text] [Related]
37. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
Cancer Prev Res (Phila); 2010 Jun; 3(6):696-706. PubMed ID: 20404000
[TBL] [Abstract][Full Text] [Related]
38. Photodynamic cell-kill analysis of breast tumor cells with a tamoxifen-pyropheophorbide conjugate.
Fernandez Gacio A; Fernandez-Marcos C; Swamy N; Dunn D; Ray R
J Cell Biochem; 2006 Oct; 99(3):665-70. PubMed ID: 16795032
[TBL] [Abstract][Full Text] [Related]
39. Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects.
Muchmore DB
Oncologist; 2000; 5(5):388-92. PubMed ID: 11040275
[TBL] [Abstract][Full Text] [Related]
40. Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin.
Gielen SC; Burger CW; Kühne LC; Hanifi-Moghaddam P; Blok LJ
J Soc Gynecol Investig; 2005 Oct; 12(7):e55-67. PubMed ID: 16202921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
